- Home
- EBF vs ALT Comparison
EBF vs ALT Comparison
Compare EBF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBF
- ALT
- Stock Information
- Founded
- EBF 1909
- ALT 1997
- Country
- EBF United States
- ALT United States
- Employees
- EBF N/A
- ALT N/A
- Industry
- EBF Office Equipment/Supplies/Services
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- EBF Consumer Discretionary
- ALT Health Care
- Exchange
- EBF Nasdaq
- ALT Nasdaq
- Market Cap
- EBF 488.0M
- ALT 397.4M
- IPO Year
- EBF N/A
- ALT N/A
- Fundamental
- Price
- EBF $17.76
- ALT $4.08
- Analyst Decision
- EBF
- ALT Strong Buy
- Analyst Count
- EBF 0
- ALT 6
- Target Price
- EBF N/A
- ALT $18.20
- AVG Volume (30 Days)
- EBF 167.2K
- ALT 11.2M
- Earning Date
- EBF 06-23-2025
- ALT 08-07-2025
- Dividend Yield
- EBF 5.64%
- ALT N/A
- EPS Growth
- EBF N/A
- ALT N/A
- EPS
- EBF 1.51
- ALT N/A
- Revenue
- EBF $388,707,000.00
- ALT $20,000.00
- Revenue This Year
- EBF $0.48
- ALT N/A
- Revenue Next Year
- EBF N/A
- ALT $507,435.66
- P/E Ratio
- EBF $11.80
- ALT N/A
- Revenue Growth
- EBF N/A
- ALT N/A
- 52 Week Low
- EBF $17.15
- ALT $2.90
- 52 Week High
- EBF $25.75
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- EBF 39.96
- ALT 39.13
- Support Level
- EBF $17.53
- ALT $3.93
- Resistance Level
- EBF $18.45
- ALT $4.79
- Average True Range (ATR)
- EBF 0.34
- ALT 0.35
- MACD
- EBF -0.07
- ALT -0.05
- Stochastic Oscillator
- EBF 20.44
- ALT 45.09
About EBF Ennis Inc.
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialities, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360º Custom LabelsSM, ColorWorx, Enfusion, among others.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.